Industry update: New treatments prove mettle in relapsed and refractory patients


CAL-101 and GA101 demonstrate active results in indolent B-cell non-Hodgkin’s lymphoma and chronic lymphocytic leukemia while a secondary analysis of a pralatrexate (Folotyn) trial shows a benefit for peripheral T-cell lymphoma patients who fail second-line therapy.

P13K inhibitor paired with chemo has promise in refractory NHL, CLL

Early results from a phase I study of CAL-101 in combination with rituximab (Rituxan) or bendamustine (Treanda) demonstrated noteworthy clinical activity in patients with relapsed or refractory indolent B cell non-Hodgkin’s lymphoma (iNHL) and chronic lymphocytic leukemia (CLL).

CAL-101, a delta-isoform-selective PI3K inhibitor, was given to patients twice per day (100 mg BID) in 28-day cycles for up to 12 cycles. Patients also received either rituximab (375 mg/m²) administered weekly for eight weeks starting on day 1 of cycle 1, or bendamustine (90 mg/m²) administered on days 1 and 2 of each cycle for six cycles (ASH 2010 abstract 2832).

Out of a dozen patients, half showed complete or partial response to the treatment regimen. Enrollment in the study is ongoing and dose escalation with CAL-101 is planned, according to manufacturer Calistoga Pharmaceuticals.

Survival advantage seen with high-dose anti-CD20 antibody

A high dose of single-agent GA101 seemed to offer a survival advantage in heavily pretreated relapsed and refractory iNHL patients. GA101 is a type II, glycoengineered and humanized monoclonal anti-CD20 antibody from Genentech.

Forty eligible patients were randomized to receive GA101 in a low-dose (400 mg) or a high-dose (1,600 mg and 800 mg) cohort in nine scheduled infusions. According to the results, six of 22 rituximab-refractory patients in the high-dose cohort had an end-of-treatment response rate of 50%. The median progression-free survival was 11.3 months in the high-dose cohort (ASH 2010 abstract 2868).

Folotyn makes good as second-line therapy in PTCL

Pralatrexate (Folotyn) was an effective second-line treatment for peripheral T-cell lymphoma (PTCL). In addition, single-agent treatment with pralatrexate compared favorably with ifosfamide/carboplatin/etoposide-based (ICE-based) regimens, indicating that pralatrexate could reverse the characteristic progressive resistance of PTCL patients to second-line chemotherapy.

A multi-institutional group of researchers, led by Andre Goy, MD, from The John Theurer Cancer Center at Hackensack University Medical Center in New Jersey, analyzed data from the PROPEL* study to assess the efficacy of pralatrexate after failure of ICE-based regimens (ASCO 2009 abstract 8561).

Of the 109 patients enrolled in PROPEL and evaluable for efficacy, a subset of 20 patients received an ICE-based regimen as second-line therapy and had disease progression at some point prior to treatment with pralatrexate (30 mg/m² weekly for 6- or 7-week cycles).

The authors reported an overall response rate of 40%, including two cases of complete responses that lead to stem cell transplantation. “Of note is the long duration of pralatrexate responses in marked contrast to the short response duration of the combination chemotherapy regimens,” the authors stated (ASH 2010 abstract 1753). Folotyn is manufactured by Allos Therapeutics.

*PROPEL = Pralatrexate in Patients with Relapsed Or Refractory Peripheral T-cell Lymphoma

Related Videos
Cretostimogene grenadenorepvec’s efficacy compares favorably with the current nonsurgical standards of care in high-risk, Bacillus Calmette Guerin–unresponsive non-muscle invasive bladder cancer.
Artificial intelligence models may be “seamlessly incorporated” into clinical workflow in the management of prostate cancer, says Eric Li, MD.
Robust genetic testing guidelines in the prostate cancer space must be supported by strong clinical research before they can be properly implemented, says William J. Catalona, MD.
Treatment with tisotumab vedotin may be a standard of care in second- or third-line recurrent or metastatic cervical cancer, says Brian Slomovitz, MD, MS, FACOG.
Future analyses will look at durvalumab/olaparib for endometrial cancer populations with TP53 and POLE alterations, as well as those with estrogen receptor and progesterone receptor positivity.
Patients with mismatch repair proficient, newly diagnosed, advanced or recurrent endometrial cancer may have enhanced benefit with the addition of olaparib to durvalumab.
Common adverse effects following treatment with lenvatinib plus pembrolizumab in the phase 3 CLEAR study include diarrhea, hypertension, and fatigue, according to Thomas E. Hutson, DO, PharmD, FACP.
Lenvatinib in combination with pembrolizumab appears to raise no new safety signals in patients with advanced clear cell renal cell carcinoma after 4 years of follow-up in the phase 3 CLEAR study.
According to Thomas E. Hutson, DO, PharmD, FACP, 4-year follow-up data from the phase 3 CLEAR study confirm the maintained benefits of lenvatinib plus pembrolizumab in patients with advanced renal cell carcinoma.
Findings from the phase 3 MIRASOL trial support mirvetuximab soravtansine as a standard treatment option for platinum-resistant ovarian cancer, according to Ritu Salani, MD.
Related Content